Page last updated: 2024-12-06

leucocyanidin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

leucocyanidin: derived from dihydro-quercetin and a precursor to cyanidin; for treatment of hemorroids [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID440833
CHEMBL ID124022
CHEBI ID11412
SCHEMBL ID1649595
MeSH IDM0041767

Synonyms (27)

Synonym
480-17-1
(2r,3s,4s)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2h-chromene-3,4,5,7-tetrol
CHEBI:11412 ,
(2r,3s,4s)-leucocyanidin
2r-(3,4-dihydroxyphenyl)chromane-3t,4t,5,7-tetrol
procyanidol
leucocyanidin
leucocianidol
2,3-trans-3,4-cis-leucocyanidin
leucocyanidol
C05906
leukocyanidine
3,4-cyanidiol
2-(3,4-dihydroxyphenyl)-3,4-dihydro-2h-1-benzopyran-3,4,5,7-tetrol
93527-39-0
leucoanthocyanidol
CHEMBL124022
flavan (tn)
D08112
leucocianidol (inn)
LMPK12020203
catechin-4beta-ol
SCHEMBL1649595
2,3-trans,3,4-cis-leucocyanidin
DTXSID70331530
Q8085718
F82290

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" On oral administration, it decreased blood sugar very significantly both in normal and moderately diabetic rats and increased serum insulin significantly in the latter at a dosage of 250 mg/kg for a 2 hr period."( Antidiabetic effect of a leucocyanidin derivative isolated from the bark of Ficus bengalensis Linn.
Augusti, KT; Kumar, RV, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
leucocyanidin
(2R,3S,4S)-leucoanthocyanidinAny leucoanthocyanidin that has 2R,3S,4S-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Flavonoid Biosynthesis1150
Leucopelargonidin and Leucocyanidin Biosynthesis314
2,3-trans-flavanols biosynthesis010
leucopelargonidin and leucocyanidin biosynthesis516
leucopelargonidin and leucocyanidin biosynthesis720
2,3-trans-flavanols biosynthesis110

Bioassays (2)

Assay IDTitleYearJournalArticle
AID234112Specific activity of 14CO2 formation from 1-[14C]-2OG in presence of anthocyanin synthase(ANS)2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
The C-4 stereochemistry of leucocyanidin substrates for anthocyanidin synthase affects product selectivity.
AID234111Specific activity of 14CO2 formation from 1-[14C]-2OG corrected for uncoupled turnover in presence of anthocyanin synthase(ANS)2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
The C-4 stereochemistry of leucocyanidin substrates for anthocyanidin synthase affects product selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (29.41)18.7374
1990's5 (29.41)18.2507
2000's2 (11.76)29.6817
2010's4 (23.53)24.3611
2020's1 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]